BT3 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Lineage Cell Therapeutics Inc

Watchlist Manager

Watchlist

Price: 1.35 EUR Market Closed

Market Cap: €395.1m

L	Lineage Cell Therapeutics Inc XBER:BT3	US
	Puradelta Lestari Tbk PT IDX:DMAS	ID
	Prosus NV AEX:PRX	NL
P	Perusahaan Gas Negara Tbk PT F:PGB1	ID
C	CME Group Inc XBER:MX4A	US
S	Synchrony Financial LSE:0LC3	US
	Metso Outotec Corp OTC:OUKPY	FI
	Duke Energy Corp NYSE:DUK	US
	Globant SA NYSE:GLOB	LU
H	Honda Motor Co Ltd SWB:HDM	JP
	North American Construction Group Ltd TSX:NOA	CA

Profitability Summary

Lineage Cell Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

99%

Strong 3Y Average Gross Margin

95%

Gross Margin is Increasing

94% > 99%

Negative Operating Margin

-150%

Negative 3Y Average Operating Margin

-249%

Operating Margin is Increasing

-223% > -150%

Negative Net Margin

-436%

Negative 3Y Average Net Margin

-312%

Declining Net Margin

-209% > -436%

Negative Free Cash Flow Margin

-134%

Negative 3Y Average Free Cash Flow Margin

-267%

Free Cash Flow Margin is Increasing

-304% > -134%

Negative ROE

-103%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-37%

ROIC is Increasing

-36% > -34%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.